Loading
Old version — revision 1
This is a fixed snapshot of Gut microbiome, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/gut-microbiome.md — the filesystem corpus, unchanged. Not an edit.
The community of bacteria, archaea, fungi and viruses living in the human intestine, and a much-claimed but weakly demonstrated lever on aging.
The gut microbiome is the community of bacteria, archaea, fungi and viruses that live in the human intestine, together with their genes, and the metabolites they produce from what the host eats. Most of it sits in the colon. It has become one of the most heavily invoked mechanisms in the biology of aging — implicated in chronic inflammation, frailty, drug response and cognition — and it is also the mechanism where the distance between what has been shown in animals and what has been shown in people is widest.
Gut bacteria ferment dietary fibre that human enzymes cannot digest, releasing short-chain fatty acids that colonocytes use as fuel. They transform bile acids, synthesise vitamins, exclude incoming pathogens by occupying niches those pathogens need, and train the developing immune system. Germ-free animals — raised in isolators and never colonised — grow abnormal gut architecture and underdeveloped lymphoid tissue, which is the cleanest demonstration that the community is not a passenger.
The composition varies enormously between healthy people. Two adults with no illness can share only a modest fraction of their bacterial species while carrying similar metabolic capacities, which is why the field increasingly reports function rather than taxonomy. That variability is also the practical obstacle to defining what a "healthy" microbiome would be, and therefore to defining dysbiosis.
Terminology"Dysbiosis" has no agreed operational definition. It is used to mean a community that differs from a comparison group, and the comparison group is usually young, healthy and Western. A word that means "different from the controls" cannot by itself carry a claim about harm, and papers using it rarely specify which departure from which reference is supposed to matter.
The standard summary is that microbial diversity falls with age and pathobionts expand. The evidence is more complicated than that summary.
The ELDERMET study characterised faecal microbiota in 178 older Irish adults and found that composition sorted people by where they lived — in the community, in day-hospital, in rehabilitation, or in long-term residential care — and that the sorting tracked dietary quality, frailty, comorbidity and inflammatory markers.1 The gradient is real. What it isolates is not age as such but the diet, medication and confinement that come with institutional care.
A second reading emphasises divergence rather than loss. Across three cohorts totalling more than nine thousand people, gut microbiomes became increasingly individual from mid-adulthood onward; among adults past about 80, continued drift toward a unique composition was seen in the healthy and was absent in the unwell, and retaining a Bacteroides-dominated community into later life predicted worse survival over four years of follow-up.2
That result was then qualified by its own field. A reanalysis of roughly 21,000 faecal microbiomes drawn from seven repositories across five continents, spanning ages 18 to 107, found that diversity and uniqueness correlate with chronological aging but not with healthy aging, and that most summary indices obscure the taxonomic changes that carry the biological signal.3 The generic feature of aging it identified was an increase in disease-associated taxa alongside depletion of a co-abundant set of health-associated ones — a compositional claim, not a diversity claim.
The animal literature is where the strong claims come from, and it is genuinely strong within its species.
Germ-free mice do not develop the age-related rise in circulating pro-inflammatory cytokines that conventionally raised mice develop; a higher proportion of them reach 600 days; and housing germ-free mice with old conventional mice, but not with young ones, raises those cytokines.4 That is a causal chain running from the community to systemic inflammation in a mammal.
In the African turquoise killifish, a naturally short-lived vertebrate, transferring gut microbiota from young donors into middle-aged fish extended lifespan, kept the recipients more active in old age, and preserved microbial diversity.5 In mice, faecal transplant from wild-type animals into two progeroid strains extended both healthspan and lifespan, and colonisation with a single species, Akkermansia muciniphila, reproduced much of the benefit; separately, heterochronic transfers in normally aging mice shifted markers of inflammation in the gut, retina and brain in both directions, aged microbiota into young recipients making them worse and young microbiota into aged recipients making them better.6
None of these is a human result. The progeroid mice were dying of a defined genetic lesion rather than of aging; the killifish is separated from humans by more than 400 million years of evolution; the heterochronic mouse work measured tissue markers, not survival.
The causality gapThe standard method for turning a microbiome association into a causal claim is to transfer a human community into a germ-free rodent and see whether the phenotype travels with it. A review of that literature found that about 95% of published human-microbiota-associated rodent studies reported the phenotype transferring — a rate the authors argue is implausibly high and better explained by publication and design bias than by the microbiome causing that many human diseases.7 The instrument on which most causal microbiome claims rest is the instrument least able to return a negative result.
One clinical use is established. Faecal microbiota transplantation prevents recurrence of Clostridioides difficile infection, an indication where the mechanism — restoring colonisation resistance after antibiotics have removed it — is unusually legible. The US regulator moved from enforcement discretion in 2013 to approving two standardised products: Rebyota, a donor-derived rectal suspension, in November 2022, and Vowst, an oral preparation of purified spores, in April 2023.8 Both are licensed to prevent recurrence, not to treat an initial infection, and neither is licensed for anything else.
Beyond that indication the human evidence is associative. Cohort studies relate composition to frailty, mortality and inflammatory markers, and cannot separate the microbiome from the diet, medication burden and illness that shape it. Randomised trials of probiotics in older adults exist in quantity but use a wide range of strains and outcome measures and report conflicting results; the field has not produced a probiotic with a demonstrated effect on survival, frailty or any accepted measure of Biological age.9 Commercial supplements sold on microbiome claims are not held to that standard at all, and microbiome testing sits alongside the other services discussed under Biohacking and grinders where the measurement outruns anything actionable derived from it.
Diet is the intervention with the clearest effect on the community and the least clear effect on aging. Fibre intake changes composition within days, and the dietary patterns associated with longevity in long-lived populations are fibre-rich; whether the microbiome mediates any part of that association, or merely registers it, is untested. The same ambiguity applies to exercise and to Caloric restriction, both of which alter the community in rodents. Spaceflight shifts the community as well, in a setting where diet, activity and medication happen to be logged in unusual detail; those changes are covered under Space medicine.
Three features of the field make overstatement easy. Composition can be measured cheaply and at scale, so associations are abundant. The community is modifiable in principle, which makes every association read as a potential intervention. And the germ-free rodent supplies an apparatus that converts an association into a causal-looking experiment without leaving the animal facility.
The result is a pattern this wiki flags elsewhere in geroscience: a mechanism with genuine biology behind it, an intervention approved for one narrow infection, and a public claim structure that reaches from mood to dementia to lifespan. Metformin and the TAME trial and Rapamycin occupy the same position from the pharmacological side — a real signal in mice and an unresolved question in people. The Geroscience hypothesis predicts that intervening on any upstream driver of aging should move many outcomes at once; the microbiome is a candidate driver for which the prediction has not been tested in humans at all.
The tractable questions are narrower than the popular ones. Whether transplant benefits any condition other than recurrent C. difficile is being tested in registered trials; several indications have produced mixed or null results, and the honest position as of 2026 is that no second indication is established. Whether defined bacterial consortia can replace donor stool would narrow the safety problem that donor screening only partly contains: recipients have died after transplants that carried drug-resistant or pathogenic E. coli from donors who had passed screening, in incidents the US regulator publicised in 2019 and 2020.10
For aging specifically, the obstacle is the same one that constrains biomarker work generally: no microbiome measure has been accepted as a surrogate endpoint, and none has the standing that even a contested composite such as an epigenetic clock has acquired, so a trial aimed at Healthspan must be powered on clinical outcomes, which makes it large and slow. Until such a trial reports, the position that fits the evidence is that the aging gut community is a real and measurable phenomenon whose causal contribution to human aging is unquantified, and that its treatment as an established lever — in the way Cellular senescence or Immunosenescence are treated — runs ahead of what anyone has shown. The strongest objection to the whole programme is that the correlations survive because the microbiome is downstream of everything: of diet, drugs, disease, activity and confinement. A marker of how a person has lived is not thereby a target.
paperClaesson, M. J. et al. "Gut microbiota composition correlates with diet and health in the elderly." Nature, 2012.↩A single Irish cohort of 178 older adults; the strongest separation is by residential setting, which co-varies with diet and medication.
paperWilmanski, T. et al. "Gut microbiome pattern reflects healthy ageing and predicts survival in humans." Nature Metabolism, 2021.↩Over 9,000 people across three cohorts; survival was assessed over roughly four years of follow-up, and the design is observational throughout.
paperGhosh, T. S., Shanahan, F. and O'Toole, P. W. "Toward an improved definition of a healthy microbiome for healthy aging." Nature Aging, 2022.↩A reanalysis of about 21,000 faecal microbiomes from seven repositories; it reports that diversity and uniqueness track chronological age rather than healthy aging.
paperThevaranjan, N. et al. "Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction." Cell Host & Microbe, 2017.↩Entirely in mice; the survival comparison is the proportion reaching 600 days in germ-free versus conventional housing, not a lifespan trial.
paperSmith, P. et al. "Regulation of life span by the gut microbiota in the short-lived African turquoise killifish." eLife, 2017.↩Recolonisation was performed on middle-aged fish after antibiotic treatment; the species has a captive lifespan of a few months.
paperBárcena, C. et al. "Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice." Nature Medicine, 2019; and Parker, A. et al. "Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain." Microbiome, 2022.↩The first used progeroid strains dying of a defined genetic lesion; the second measured inflammatory and retinal markers in normally aging mice and did not measure lifespan.
paperWalter, J., Armet, A. M., Finlay, B. B. and Shanahan, F. "Establishing or Exaggerating Causality for the Gut Microbiome: Lessons from Human Microbiota-Associated Rodents." Cell, 2020.↩A critique of the field's principal causal instrument, written by microbiome researchers rather than by outside sceptics.
regulatorUS Food and Drug Administration. "FDA Approves First Fecal Microbiota Product" (Rebyota), 30 November 2022; and approval of Vowst (fecal microbiota spores, live-brpk), 26 April 2023.↩Both are indicated to prevent recurrence of C. difficile infection in adults after standard antibiotic therapy, not to treat it.
paperHutchinson, A. N. et al. "The Effect of Probiotics on Health Outcomes in the Elderly: A Systematic Review of Randomized, Placebo-Controlled Studies." Microorganisms, 2021.↩Trials in healthy older adults used heterogeneous strains and endpoints; the review synthesises them narratively rather than pooling them into an effect estimate.
regulatorUS Food and Drug Administration. Safety alerts on faecal microbiota for transplantation, 13 June 2019 and 12 March 2020.↩The 2019 alert concerns two immunocompromised recipients infected by drug-resistant E. coli from one donor, one fatally; the 2020 alert concerns six recipients infected from a stool bank, two of whom died.